Bristol-Myers Squibb Stock - Insider option exercise adds to board holdings

Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 19:41 CEST. Details in the imprint.

Bristol-Myers Squibb (US1078421011) has reported fresh insider activity in its stock. According to a Form 4 filing with the U.S. Securities and Exchange Commission, board member Julia A. Haller recently exercised stock options and retained the resulting shares.

What the SEC filing shows

According to a recent Form 4 summarized by StockTitan, director Julia A. Haller exercised options for 20,460 Bristol-Myers Squibb shares at an exercise price of $53.76 on 06/15/2026 and chose to hold all acquired shares rather than sell them. The Form 4 overview highlights the transaction details.

Following this transaction, Haller’s direct ownership rose to 34,079 Bristol-Myers Squibb shares, while the option grant covering the 20,460 shares has now been fully exercised. Such insider moves are routinely disclosed but are often closely watched as a signal of management’s long-term alignment with shareholders.

Operations and strategy backdrop

Operationally, Bristol-Myers Squibb continues to focus on specialty medicines across oncology, hematology, immunology and cardiovascular disease, anchored by blockbuster therapies such as Eliquis and Opdivo. The group has emphasized a pipeline-driven strategy with a series of recent product launches and late-stage candidates.

Analysts tracking the company point to the ongoing patent cliff on older products but also to a growing contribution from newer drugs, including cell therapies and targeted oncology agents, which are intended to support revenue beyond this decade. Management has repeatedly underlined disciplined capital allocation between R&D, bolt-on M&A and shareholder returns in its recent investor presentations.

How the company makes money

Bristol-Myers Squibb generates most of its revenue from prescription medicines in oncology, hematology, immunology and cardiovascular indications, with Eliquis, the oral anticoagulant co-developed with Pfizer, and Opdivo, an immuno-oncology therapy, among its largest global products.

Where the stock trades today

The shares of Bristol-Myers Squibb (US1078421011) trade on the New York Stock Exchange at $57.60 as of 06/17/2026, 17:30 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.